Growth factor analogs

Details Growth factor analogs Growth factor analogs

2005-02-04

2008-08-19

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07414028

ABSTRACT:
The invention provides synthetic heparin-binding growth factor analogs of formulas I or II as given in the specification, having two peptide chains branched from a dipeptide branch moiety composed of at least one and preferably two trifunctional amino acid residues, which peptide chain or chains bind a heparin-binding growth factor receptor. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.

REFERENCES:
patent: 4172128 (1979-10-01), Thiele et al.
patent: 4563350 (1986-01-01), Nathan et al.
patent: 5563046 (1996-10-01), Mascarenhas et al.
patent: 5608035 (1997-03-01), Yanofsky et al.
patent: 5635597 (1997-06-01), Barrett et al.
patent: 5643873 (1997-07-01), Barrett et al.
patent: 5648458 (1997-07-01), Cwirla et al.
patent: 5654276 (1997-08-01), Barrett et al.
patent: 5668110 (1997-09-01), Barrett et al.
patent: 5674977 (1997-10-01), Gariepy
patent: 5679637 (1997-10-01), Lappi et al.
patent: 5679673 (1997-10-01), Bowen et al.
patent: 5684136 (1997-11-01), Godowski
patent: 5728802 (1998-03-01), Barrett et al.
patent: 5759515 (1998-06-01), Rhodes et al.
patent: 5767234 (1998-06-01), Yanofsky et al.
patent: 5770704 (1998-06-01), Godowski
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5786322 (1998-07-01), Barrett et al.
patent: 5786331 (1998-07-01), Barrett et al.
patent: 5789182 (1998-08-01), Yayon et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5861476 (1999-01-01), Barrett et al.
patent: 5866113 (1999-02-01), Hendriks et al.
patent: 5869451 (1999-02-01), Dower et al.
patent: 5880096 (1999-03-01), Barrett et al.
patent: 5902799 (1999-05-01), Herrmann et al.
patent: 5932462 (1999-08-01), Harris et al.
patent: 5952474 (1999-09-01), Kayman et al.
patent: 5955588 (1999-09-01), Tsang et al.
patent: 5965532 (1999-10-01), Bachovchin
patent: 5989866 (1999-11-01), Deisher et al.
patent: 5994104 (1999-11-01), Anderson et al.
patent: 6001364 (1999-12-01), Rose et al.
patent: 6011002 (2000-01-01), Pastan et al.
patent: 6030812 (2000-02-01), Bauer et al.
patent: 6051648 (2000-04-01), Rhee et al.
patent: 6121236 (2000-09-01), Ben-Sasson
patent: 6168784 (2001-01-01), Offord et al.
patent: 6174530 (2001-01-01), Rose et al.
patent: 6174721 (2001-01-01), Innis
patent: 6214795 (2001-04-01), Benjamin et al.
patent: 6217873 (2001-04-01), Rose et al.
patent: 6235716 (2001-05-01), Ben-Sasson
patent: 6251864 (2001-06-01), Dower et al.
patent: 6284503 (2001-09-01), Caldwell et al.
patent: 6294359 (2001-09-01), Fiddes et al.
patent: 6323323 (2001-11-01), Sledziewski et al.
patent: 6326468 (2001-12-01), Canne et al.
patent: 6342591 (2002-01-01), Zamora et al.
patent: 6350731 (2002-02-01), Jehanli et al.
patent: 6377349 (2002-04-01), Fercher
patent: 6451543 (2002-09-01), Kochendoerfer et al.
patent: 2003/0224996 (2003-12-01), Opperman et al.
patent: WO00/18921 (2000-04-01), None
patent: WO02/04015 (2002-01-01), None
patent: WO-02/20033 (2002-03-01), None
patent: WO0219963 (2002-03-01), None
patent: WO-02/062823 (2002-08-01), None
patent: WO 02062823 (2002-08-01), None
Shen WC, “Poly(L-lysine) has different membrane transport and drug-carrier properties when complexed with heparin,” Proc Natl Acad Sci U S A. Dec. 1981;78(12):7589-93.
Tung CH et al, “Novel branching membrane translocational peptide as gene delivery vector,” Bioorg Med Chem. Nov. 2002;10(11):3609-14.
Andrades, Jose A., et al., “A Recombinant Human TGF-B1 Fusion Protein with Collagen-Binding Domain Promostes Migration, Growth, and Differentiation of Bone Marrow Mesenchymal Cells”,Experimental Cell Research, (1999),485-498.
Ballinger, Marcus D., et al., “Semirational design of a potent, artificial agonist of fibroblast growth factor receptors”,Nature Biotechnology, (1999),1199-1204.
Binetruy-Tournaire, Roselyne, et al., “Identification of a Peptide Blocking Vascular Endothelial Growth Factor (VEGF)-mediated Angiogenesis”,The EMBO Journal, vol. 19, No. 7, (2000),1525-1533.
Brennand, David M., et al., “Identification of a Cyclic Peptide Inhibitor of Platelet-Derived Growth Factor-BB Receptor-Binding and Mitogen-Induced DNA Synthesis in Human Fibroblasts”,FEBS Letters, 413, (1997),70-74.
Carmeliet, Peter , et al., “Growing Better Blood Vessels”,Nature Biotechnology, (2001),1019-1020.
Dawson, Philip E., et al., “Synthesis of Native Proteins by Chemical Ligation”,Annu. Rev. Biochem.2000, 69, (2000),923-960.
Dikov, Michael M., et al., “A Functional Fibroblast Growth Factor-1 Immunoglobulin Fusion Protein”,The Journal of Biological Chemistry, (1998),15811-15817.
Engstrom, Ulla , et al., “Identification of a Peptide Antagonist for Platelet-Derived Growth Factor”,The Journal of Biological Chemistry, vol. 273, No. 25, (1998),15811-15817.
Eom, Khee D., et al., “Tandem Ligation of Multipartite Peptides with Cell-Permeable Activity”,J. Am. Chem. Soc., 2003, 125, (2003),73-83.
Gay, Cyril, G., et al., “Interleukin 1 regulated heparin-binding growth factor 2 gene expression in vascular smooth muscle cells”,Proc. Natl. Acad. Sci. USA, vol. 88, (Jan. 1991),296-300.
Hasan, Maemunah , et al., “IL-12 is a Heparin-Binding Cytokine”,The Journal of Immunology, (1999), 1064-1070.
Hoke, David E., et al., “A Heparin Binding Synthetic Peptide from Human HIP/RPL29 Fails to Specifically Differentiate Between Anticoagulantly Active and Inactive Species of Heparin”,Journal of Negative Results in BioMedicine, (2003).
Kochendoefer, Gerd , et al., “Design and Chemical Synthesis of Homogenous Polymer-Modified Erythropotesis Protein”,Science, vol. 299, (Feb. 7, 2003).
Ostman, Arne , et al., “Identification of Three Amino Acids in the Platelet-Derived Growth Factor (PDGF) B-chain that are Important for Binding to the PDGF B-Receptor”,The Journal of Biological Chemistry, vol. 266, No. 16, Issue of Jun. 5, 1991, 10073-10077.
Paris, Francois , et al., “Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice”,Science, (2001),293-297.
Pellegrini, Luca , “Role of heparan sulfate in fibroblast growth factor signaling a structural view”,Structural Biology, (2001),629-634.
Ray , Jasohara , et al., “A 10-amino acid sequence of fibroblast growth factor 2 is sufficient for its mitogenic activity on neural progenitor cells”,Proc. Natl. Acad. Sci. USA, (1997),7047-7052.
Richardson, Thomas P., et al., “Polymeric system for dual growth factor delivery”,Nature Biotechnology, (2001),293-297.
Rusnati, Marco , et al., “avB3 Integrin Mediates the Cell-adhesive Capacity and Biological Activity of Basic Fibroblast Growth Factor (FGF-2) in Cultured Endothelial Cells”,Molecular Biology of the Cell, (1997),2449-2461.
Sood, R. , et al., “MDS1/EVI1 enhances TGF-B1 signaling and strengthens its growth-inhibitory effect, but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3:21), abrogates growth-inhibition in response to TGF-B1”,Leukemia, (1999),348-357.
Takizawa, Takuma, et al., “Directly Linked Soluble IL-6 Receptor-IL-6 Fusion Protein Induces Astrocyte Differentiation from Neuroepithelial Cells Via Activation of STAT3”,Cytokine, (2001),272-279.
Verrecchio, Angela , et al., “Design of Peptides with High Affinities for Heparin and Endothelial Cell Proteoglycans”,The Journal of Biological Chemistry, (2000),7701-7707.
Verrecchio, Angela , “Design of Peptides with High Affinites for Heparin and Endothelial Cell Proteoglycans”,The Journal of Biological Chemistry, vol. 275, No. 11, (Mar. 17, 2000),7701-7707.
Yoneda, Atsuko , “Engineering of an FGF-proteoglycan fusion protein with heparin-independent, mitogenic activity”,Nature Biotechnologyvol. 18, (Jun. 2000),641-644.
Yoneda, Atsuko, et al., “Engineering of an FGF-proteoglycan fusion protein with heparin-independent, mitogen

Affiliated with

Also associated with

Rating

Growth factor analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Growth factor analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Growth factor analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4002064